Avalo Therapeutics (AVTX) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing therapeutics targeting the interleukin-1β (IL-1β) pathway for immune-mediated inflammatory diseases.

• Lead product candidate, abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody with positive Phase 2 data in hidradenitis suppurativa (HS); plans to advance to Phase 3 in 2027.

• Pipeline includes AVTX-010, a next-generation long-acting anti-IL-1β mAb, with IND application targeted for H1 2027.

Financial performance and metrics

• 52,902,989 shares of common stock outstanding as of July 10, 2026.

• Common stock last traded at $17.88 per share on July 16, 2026, on Nasdaq under the symbol "AVTX."

Use of proceeds and capital allocation

• No proceeds will be received from this offering; all shares are being sold by selling stockholders.

• Company will pay all registration-related expenses except brokerage fees and commissions.